Lentiviral-mediated short hairpin RNA silencing of APE1 suppresses hepatocellular carcinoma proliferation and migration: A potential therapeutic target for hepatoma treatment

Zheng,Zhi-Hua; Du,Wei; Li,Yan-Ju; Gao,Mei-Qin; Huang,Ai-Min; Liu,Jing-Feng

doi:10.3892/or.2015.3976

Lentiviral-mediated short hairpin RNA silencing of APE1 suppresses hepatocellular carcinoma proliferation and migration: A potential therapeutic target for hepatoma treatment

Authors:
- Zhi-Hua Zheng
- Wei Du
- Yan-Ju Li
- Mei-Qin Gao
- Ai-Min Huang
- Jing-Feng Liu
View Affiliations

Affiliations: Department of Pathology, Quanzhou Medical College, Quanzhou, Fujian 362100, P.R. China, Department of Pathology and Institute of Oncology, Fujian Medical University, Fuzhou, Fujian 350004, P.R. China, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian 350025, P.R. China
Published online on: May 13, 2015 https://doi.org/10.3892/or.2015.3976
Pages: 95-102

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Apurinic/apyrimidinic endonuclease-1 (APE1) is a protein involved in DNA repair and transcriptional regulation of gene expression. APE1 expression was reported to be correlated with poor prognosis in hepatocellular carcinoma (HCC) patients. Based on our previous study, we hypothesized that APE1 may be involved in the metastatic progression of HCC. Thus, the present study aimed to investigate the knockdown effect of APE1 using shRNA in HCC and demonstrate that silencing of APE1 in MHCC97-H cells can decrease the oncogenic transforming potential in vitro and reduce the growth of HCC tumor xenografts in vivo. Silencing of APE1 expression decreased the cell proliferation and survival, reduced the cell adhesion ability in Matrigel or fibronectin-coated plates and suppressed the cell migration and invasion in a Transwell assay of HCC cells. In the xenograft study, tumor growth was markedly inhibited in the APE1-silenced group. Silencing of APE1 in MHCC97-H cells decreased the oncogenic transforming potential in vitro and reduced the growth of HCC tumor xenografts in vivo. Inhibition of APE1 may present a novel therapeutic approach for the treatment of HCC.

View Figures

View References

1	Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
3	Tang ZY: Hepatocellular carcinoma – cause, treatment and metastasis. World J Gastroenterol. 7:445–454. 2001.
4	Bruix J and Sherman M: American association for the study of liver diseases: management of hepatocellular carcinoma: an update. Hepatology. 53:1020–1022. 2011. View Article : Google Scholar : PubMed/NCBI
5	Abbotts R and Madhusudan S: Human AP endonuclease 1 (APE1): from mechanistic insights to druggable target in cancer. Cancer Treat Rev. 36:425–435. 2010. View Article : Google Scholar : PubMed/NCBI
6	Kelley MR, Cheng L, Foster R, Tritt R, Jiang J, Broshears J and Koch M: Elevated and altered expression of the multifunctional DNA base excision repair and redox enzyme Ape1/ref-1 in prostate cancer. Clin Cancer Res. 7:824–830. 2001.PubMed/NCBI
7	Yoo DG, Song YJ, Cho EJ, Lee SK, Park JB, Yu JH, Lim SP, Kim JM and Jeon BH: Alteration of APE1/ref-1 expression in non-small cell lung cancer: the implications of impaired extracellular superoxide dismutase and catalase antioxidant systems. Lung Cancer. 60:277–284. 2008. View Article : Google Scholar
8	Xiang DB, Chen ZT, Wang D, Li MX, Xie JY, Zhang YS, Qing Y, Li ZP and Xie J: Chimeric adenoviral vector Ad5/F35-mediated APE1 siRNA enhances sensitivity of human colorectal cancer cells to radiotherapy in vitro and in vivo. Cancer Gene Ther. 15:625–635. 2008. View Article : Google Scholar : PubMed/NCBI
9	Tanner B, Grimme S, Schiffer I, Heimerdinger C, Schmidt M, Dutkowski P, Neubert S, Oesch F, Franzen A, Kölbl H, et al: Nuclear expression of apurinic/apyrimidinic endonuclease increases with progression of ovarian carcinomas. Gynecol Oncol. 92:568–577. 2004. View Article : Google Scholar : PubMed/NCBI
10	Herring CJ, West CM, Wilks DP, Davidson SE, Hunter RD, Berry P, Forster G, MacKinnon J, Rafferty JA, Elder RH, et al: Levels of the DNA repair enzyme human apurinic/apyrimidinic endonuclease (APE1, APEX, Ref-1) are associated with the intrinsic radiosensitivity of cervical cancers. Br J Cancer. 78:1128–1133. 1998. View Article : Google Scholar : PubMed/NCBI
11	Wang D, Luo M and Kelley MR: Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: Enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition. Mol Cancer Ther. 3:679–686. 2004.PubMed/NCBI
12	Cun Y, Dai N, Xiong C, Li M, Sui J, Qian C, Li Z and Wang D: Silencing of APE1 enhances sensitivity of human hepatocellular carcinoma cells to radiotherapy in vitro and in a xenograft model. PLoS One. 8:e553132013. View Article : Google Scholar : PubMed/NCBI
13	Tell G, Quadrifoglio F, Tiribelli C and Kelley MR: The many functions of APE1/Ref-1: not only a DNA repair enzyme. Antioxid Redox Signal. 11:601–620. 2009. View Article : Google Scholar
14	Bhakat KK, Mantha AK and Mitra S: Transcriptional regulatory functions of mammalian AP-endonuclease (APE1/Ref-1), an essential multifunctional protein. Antioxid Redox Signal. 11:621–638. 2009. View Article : Google Scholar
15	Li M and Wilson DM III: Human apurinic/apyrimidinic endo-nuclease 1. Antioxid Redox Signal. 20:678–707. 2014. View Article : Google Scholar :
16	Di Maso V, Avellini C, Crocè LS, Rosso N, Quadrifoglio F, Cesaratto L, Codarin E, Bedogni G, Beltrami CA, Tell G, et al: Subcellular localization of APE1/Ref-1 in human hepatocellular carcinoma: possible prognostic significance. Mol Med. 13:89–96. 2007. View Article : Google Scholar : PubMed/NCBI
17	Zhang QH, Xiang DB, Li MX, Liao PL, Li ZP and Wang D: Expression of DNA repair gene apurinic/apyrimidinic endonuclease 1 and its correlation with the expression of mutant p53 in hepatocellular carcinoma. Chin J Dig Surg. 8:453–456. 2009.
18	Huang AM, Zheng ZH, Liu JF, Zang SB, Gao LY and Chen SP: The expression of APE1 gene and its clinical implication in hepatocellular carcinoma: a study using tissue chip assay. Zhonghua Gan Zang Bing Za Zhi. 16:542–543. 2008.In Chinese. PubMed/NCBI
19	Li YJ, Zheng ZH, Liu JF, Gao MQ and Huang AM: Construction and identification of a lentiviral vector for RNA interference of APE1 gene. J Fujian Med Univ. 44:86–90. 2010.
20	Casey RC, Oegema TR Jr, Skubitz KM, Pambuccian SE, Grindle SM and Skubitz AP: Cell membrane glycosylation mediates the adhesion, migration, and invasion of ovarian carcinoma cells. Clin Exp Metastasis. 20:143–152. 2003. View Article : Google Scholar : PubMed/NCBI
21	Fischer AH, Jacobson KA, Rose J and Zeller R: Hematoxylin and eosin staining of tissue and cell sections. CSH Prot. 2008:pdb.prot4986. 2008.
22	Di Maio M, De Maio E, Perrone F, Pignata S and Daniele B: Hepatocellular carcinoma: systemic treatments. J Clin Gastroenterol. 35(Suppl 2): S109–S114. 2002. View Article : Google Scholar : PubMed/NCBI
23	Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al: SHARP investigators study group: sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
24	Llovet JM and Bruix J: Molecular targeted therapies in hepato-cellular carcinoma. Hepatology. 48:1312–1327. 2008. View Article : Google Scholar : PubMed/NCBI
25	Zou GM and Maitra A: Small-molecule inhibitor of the AP endo-nuclease 1/REF-1 E3330 inhibits pancreatic cancer cell growth and migration. Mol Cancer Ther. 7:2012–2021. 2008. View Article : Google Scholar : PubMed/NCBI
26	Zou GM, Karikari C, Kabe Y, Handa H, Anders RA and Maitra A: The APE-1/Ref-1 redox antagonist E3330 inhibits the growth of tumor endothelium and endothelial progenitor cells: therapeutic implications in tumor angiogenesis. J Cell Physiol. 219:209–218. 2009. View Article : Google Scholar
27	Morris KV and Rossi JJ: Lentiviral-mediated delivery of siRNAs for antiviral therapy. Gene Ther. 13:553–558. 2006. View Article : Google Scholar : PubMed/NCBI
28	Ando K, Hirao S, Kabe Y, Ogura Y, Sato I, Yamaguchi Y, Wada T and Handa H: A new APE1/Ref-1-dependent pathway leading to reduction of NF-kappaB and AP-1, and activation of their DNA-binding activity. Nucleic Acids Res. 36:4327–4336. 2008. View Article : Google Scholar : PubMed/NCBI
29	Eferl R and Wagner EF: AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer. 3:859–868. 2003. View Article : Google Scholar : PubMed/NCBI
30	Liu P, Kimmoun E, Legrand A, Sauvanet A, Degott C, Lardeux B and Bernuau D: Activation of NF-kappa B, AP-1 and STAT transcription factors is a frequent and early event in human hepa-tocellular carcinomas. J Hepatol. 37:63–71. 2002. View Article : Google Scholar : PubMed/NCBI
31	Yuen MF, Wu PC, Lai VC, Lau JY and Lai CL: Expression of c-Myc, c-Fos, and c-jun in hepatocellular carcinoma. Cancer. 91:106–112. 2001. View Article : Google Scholar : PubMed/NCBI
32	Ozanne BW, McGarry L, Spence HJ, Johnston I, Winnie J, Meagher L and Stapleton G: Transcriptional regulation of cell invasion: AP-1 regulation of a multigenic invasion programme. Eur J Cancer. 36:1640–1648. 2000. View Article : Google Scholar : PubMed/NCBI
33	Westermarck J and Kähäri VM: Regulation of matrix metallo-proteinase expression in tumor invasion. FASEB J. 13:781–792. 1999.PubMed/NCBI
34	Lam E, Kilani RT, Li Y, Tredget EE and Ghahary A: Stratifin-induced matrix metalloproteinase-1 in fibroblast is mediated by c-fos and p38 mitogen-activated protein kinase activation. J Invest Dermatol. 125:230–238. 2005.PubMed/NCBI
35	Fishel ML and Kelley MR: The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target. Mol Aspects Med. 28:375–395. 2007. View Article : Google Scholar : PubMed/NCBI